PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
April 3, 2026Blood Cancer JournalOpen Access

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShaji KumarKWKatja C. WeiselPSPaul Spin

Discussion

Loading...

Member takes

Overview

Phase 1/2 study shows linvoseltamab improves outcomes in triple-class exposed multiple myeloma, suggesting a promising treatment option.

Key Points

  • To evaluate the effectiveness of linvoseltamab compared to real-world standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.
  • Conducted a Phase 1/2 study with linvoseltamab in patients with relapsed/refractory multiple myeloma.
  • Compared outcomes with an external control group from electronic health records.
  • Applied inverse probability of treatment weighting to balance cohorts.
  • Linvoseltamab showed a higher objective response rate compared to real-world standard-of-care.
  • Significantly longer median progression-free survival observed with linvoseltamab.
  • Lower risks of time to next treatment and overall survival loss compared to standard-of-care.

Cite This Study

Kumar et al. (2026) studied this question.

synapsesocial.com/papers/69cf5cd15a333a821460a5f0https://doi.org/10.1038/s41408-026-01470-6
View Full Paper
Ask AI
Bookmark
Share